Literature DB >> 21537084

Transcription intermediary factor 1γ is a tumor suppressor in mouse and human chronic myelomonocytic leukemia.

Romain Aucagne1, Nathalie Droin, Jérôme Paggetti, Brice Lagrange, Anne Largeot, Arlette Hammann, Amandine Bataille, Laurent Martin, Kai-Ping Yan, Pierre Fenaux, Régine Losson, Eric Solary, Jean-Noël Bastie, Laurent Delva.   

Abstract

Transcription intermediary factor 1γ (TIF1γ) was suggested to play a role in erythropoiesis. However, how TIF1γ regulates the development of different blood cell lineages and whether TIF1γ is involved in human hematological malignancies remain to be determined. Here we have shown that TIF1γ was a tumor suppressor in mouse and human chronic myelomonocytic leukemia (CMML). Loss of Tif1g in mouse HSCs favored the expansion of the granulo-monocytic progenitor compartment. Furthermore, Tif1g deletion induced the age-dependent appearance of a cell-autonomous myeloproliferative disorder in mice that recapitulated essential characteristics of human CMML. TIF1γ was almost undetectable in leukemic cells of 35% of CMML patients. This downregulation was related to the hypermethylation of CpG sequences and specific histone modifications in the gene promoter. A demethylating agent restored the normal epigenetic status of the TIF1G promoter in human cells, which correlated with a reestablishment of TIF1γ expression. Together, these results demonstrate that TIF1G is an epigenetically regulated tumor suppressor gene in hematopoietic cells and suggest that changes in TIF1γ expression may be a biomarker of response to demethylating agents in CMML.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21537084      PMCID: PMC3104753          DOI: 10.1172/JCI45213

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  55 in total

1.  Hematopoiesis controlled by distinct TIF1gamma and Smad4 branches of the TGFbeta pathway.

Authors:  Wei He; David C Dorn; Hediye Erdjument-Bromage; Paul Tempst; Malcolm A S Moore; Joan Massagué
Journal:  Cell       Date:  2006-06-02       Impact factor: 41.582

2.  Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia.

Authors:  Hagop Kantarjian; Yasuhiro Oki; Guillermo Garcia-Manero; Xuelin Huang; Susan O'Brien; Jorge Cortes; Stefan Faderl; Carlos Bueso-Ramos; Farhad Ravandi; Zeev Estrov; Alessandra Ferrajoli; William Wierda; Jianqin Shan; Jan Davis; Francis Giles; Hussain I Saba; Jean-Pierre J Issa
Journal:  Blood       Date:  2006-08-01       Impact factor: 22.113

3.  TIF1gamma, a novel member of the transcriptional intermediary factor 1 family.

Authors:  L Venturini; J You; M Stadler; R Galien; V Lallemand; M H Koken; M G Mattei; A Ganser; P Chambon; R Losson; H de Thé
Journal:  Oncogene       Date:  1999-02-04       Impact factor: 9.867

4.  A microenvironment-induced myeloproliferative syndrome caused by retinoic acid receptor gamma deficiency.

Authors:  Carl R Walkley; Gemma Haines Olsen; Sebastian Dworkin; Stewart A Fabb; Jeremy Swann; Grant A McArthur; Susan V Westmoreland; Pierre Chambon; David T Scadden; Louise E Purton
Journal:  Cell       Date:  2007-06-15       Impact factor: 41.582

5.  Loss of Trim24 (Tif1alpha) gene function confers oncogenic activity to retinoic acid receptor alpha.

Authors:  Konstantin Khetchoumian; Marius Teletin; Johan Tisserand; Manuel Mark; Benjamin Herquel; Mihaela Ignat; Jessica Zucman-Rossi; Florence Cammas; Thierry Lerouge; Christelle Thibault; Daniel Metzger; Pierre Chambon; Régine Losson
Journal:  Nat Genet       Date:  2007-11-18       Impact factor: 38.330

Review 6.  TGFbeta-SMAD signal transduction: molecular specificity and functional flexibility.

Authors:  Bernhard Schmierer; Caroline S Hill
Journal:  Nat Rev Mol Cell Biol       Date:  2007-12       Impact factor: 94.444

7.  Generation of mice with a conditional allele for Trim33.

Authors:  Jieun Kim; Vesa Kaartinen
Journal:  Genesis       Date:  2008-06       Impact factor: 2.487

8.  Inhibition of TGF-beta with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression.

Authors:  Swati Biswas; Marta Guix; Cammie Rinehart; Teresa C Dugger; Anna Chytil; Harold L Moses; Michael L Freeman; Carlos L Arteaga
Journal:  J Clin Invest       Date:  2007-04-05       Impact factor: 14.808

9.  Rb regulates interactions between hematopoietic stem cells and their bone marrow microenvironment.

Authors:  Carl R Walkley; Jeremy M Shea; Natalie A Sims; Louise E Purton; Stuart H Orkin
Journal:  Cell       Date:  2007-06-15       Impact factor: 41.582

10.  FLT3 mutations confer enhanced proliferation and survival properties to multipotent progenitors in a murine model of chronic myelomonocytic leukemia.

Authors:  Benjamin H Lee; Zuzana Tothova; Ross L Levine; Kristina Anderson; Natalija Buza-Vidas; Dana E Cullen; Elizabeth P McDowell; Jennifer Adelsperger; Stefan Fröhling; Brian J P Huntly; Miloslav Beran; Sten Eirik Jacobsen; D Gary Gilliland
Journal:  Cancer Cell       Date:  2007-10       Impact factor: 31.743

View more
  53 in total

1.  Loss of TRIM33 causes resistance to BET bromodomain inhibitors through MYC- and TGF-β-dependent mechanisms.

Authors:  Xiarong Shi; Valia T Mihaylova; Leena Kuruvilla; Fang Chen; Stephen Viviano; Massimiliano Baldassarre; David Sperandio; Ruben Martinez; Peng Yue; Jamie G Bates; David G Breckenridge; Joseph Schlessinger; Benjamin E Turk; David A Calderwood
Journal:  Proc Natl Acad Sci U S A       Date:  2016-07-18       Impact factor: 11.205

2.  Trim33 is required for appropriate development of pre-cardiogenic mesoderm.

Authors:  Sudha Rajderkar; Jeffrey M Mann; Christopher Panaretos; Kenji Yumoto; Hong-Dong Li; Yuji Mishina; Benjamin Ralston; Vesa Kaartinen
Journal:  Dev Biol       Date:  2019-03-30       Impact factor: 3.582

3.  Expression of the dermatomyositis autoantigen transcription intermediary factor 1γ in regenerating muscle.

Authors:  Payam Mohassel; Paul Rosen; Livia Casciola-Rosen; Katherine Pak; Andrew L Mammen
Journal:  Arthritis Rheumatol       Date:  2015-01       Impact factor: 10.995

Review 4.  Chronic myelomonocytic leukemia prognostic classification and management: evidence base and current practice.

Authors:  Dorothée Selimoglu-Buet; Eric Solary
Journal:  Curr Hematol Malig Rep       Date:  2014-12       Impact factor: 3.952

5.  Characteristic repartition of monocyte subsets as a diagnostic signature of chronic myelomonocytic leukemia.

Authors:  Dorothée Selimoglu-Buet; Orianne Wagner-Ballon; Véronique Saada; Valérie Bardet; Raphaël Itzykson; Laura Bencheikh; Margot Morabito; Elisabeth Met; Camille Debord; Emmanuel Benayoun; Anne-Marie Nloga; Pierre Fenaux; Thorsten Braun; Christophe Willekens; Bruno Quesnel; Lionel Adès; Michaela Fontenay; Philippe Rameau; Nathalie Droin; Serge Koscielny; Eric Solary
Journal:  Blood       Date:  2015-04-07       Impact factor: 22.113

6.  Adenovirus E4orf3 targets transcriptional intermediary factor 1γ for proteasome-dependent degradation during infection.

Authors:  Natalie A Forrester; Rakesh N Patel; Thomas Speiseder; Peter Groitl; Garry G Sedgwick; Neil J Shimwell; Robert I Seed; Pól Ó Catnaigh; Christopher J McCabe; Grant S Stewart; Thomas Dobner; Roger J A Grand; Ashley Martin; Andrew S Turnell
Journal:  J Virol       Date:  2011-12-28       Impact factor: 5.103

7.  DNA methylation profile in chronic myelomonocytic leukemia associates with distinct clinical, biological and genetic features.

Authors:  Laura Palomo; Roberto Malinverni; Marta Cabezón; Blanca Xicoy; Montserrat Arnan; Rosa Coll; Helena Pomares; Olga García; Francisco Fuster-Tormo; Javier Grau; Evarist Feliu; Francesc Solé; Marcus Buschbeck; Lurdes Zamora
Journal:  Epigenetics       Date:  2018-02-06       Impact factor: 4.528

8.  Molecular similarity between myelodysplastic form of chronic myelomonocytic leukemia and refractory anemia with ring sideroblasts.

Authors:  Véronique Gelsi-Boyer; Nathalie Cervera; François Bertucci; Mandy Brecqueville; Pascal Finetti; Anne Murati; Christine Arnoulet; Marie-Joelle Mozziconacci; Ken I Mills; Nicholas C P Cross; Norbert Vey; Daniel Birnbaum
Journal:  Haematologica       Date:  2012-10-12       Impact factor: 9.941

9.  The E3 ubiquitin ligase tripartite motif 33 is essential for cytosolic RNA-induced NLRP3 inflammasome activation.

Authors:  Leiyun Weng; Hiroki Mitoma; Coline Trichot; Coline Tricot; Musheng Bao; Ying Liu; Zhiqiang Zhang; Yong-Jun Liu
Journal:  J Immunol       Date:  2014-08-29       Impact factor: 5.422

Review 10.  Ubiquitination and deubiquitination emerge as players in idiopathic pulmonary fibrosis pathogenesis and treatment.

Authors:  Shuang Li; Jing Zhao; Dong Shang; Daniel J Kass; Yutong Zhao
Journal:  JCI Insight       Date:  2018-05-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.